### 42532 Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices

their retinal illumination output) and will accept a near IR CCD camera connected to a TV mounted on the photographic-camera port.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 9, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 2013–16950 Filed 7–15–13; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** 

**National Institutes of Health**

**Prospective Grant of Start-Up Exclusive Evaluation Option License:**  **Methods of Treating Giardiasis Using Available Compounds** 

**AGENCY :**  National Institutes of Health, HHS.

**ACTION :**  Notice.

**SUMMARY :**  This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive evaluation option license to practice the inventions embodied in U.S. provisional Applications 61/392,096 (E–211–2010/ 0–US–01) filed October 12, 2010 and 61/411,509 filed November 9, 2010 (E– 211–2010/1–US–01); PCT application No. PCT/US2011/055902 filed October 12, 2011 (E–211–2010/2–PCT–01); US patent application No. 13/878,832 filed April 11, 2013 (E–211–2010/2–US–06); European patent application No. 11773158.8 filed May 2, 2013 (E–211– 2010/2–EP–04); Canadian application No. 2,814,694 filed April 11, 2013 (E– 211–2010/2–CA–03); Australia application No. 2011316657 filed April 12, 2013 (E–211–2010/2–AU–02); and Indian application No. 1137/KOLNP/ 2013 filed April 22, 2013 (E–211–2010/ 2–IN–05); each entitled ‘‘Methods of Treating Giardiasis’’ by Wei Zheng et al. to BrioMed, Inc., having a place of business at 1743 S. Westgate Ave, Los Angeles, CA 90025 USA. The patent rights in this invention have been assigned to the United States of America and the University of Maryland.

**DATES :**  Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before July 31, 2013 will be considered.

**ADDRESSES :**  Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Tedd Fenn, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Email: Tedd.Fenn@mail.nih.gov; Telephone: 301–435–5031; Facsimile: 301–402–
0220.

**SUPPLEMENTARY INFORMATION :**  The prospective start-up exclusive evaluation option license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective start-up exclusive evaluation option license may be granted unless, within fifteen (15) days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO–1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17- allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world.

The proposed field of exclusivity may be limited to therapeutics for treatment of Giardia infection in mammals.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 9, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 2013–16948 Filed 7–15–13; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HOMELAND SECURITY** 

**Cooperative Research and Development Agreement (CRADA)**  **Opportunity With the Department of Homeland Security for the**  **Development of a Foot-and-Mouth Disease 3ABC ELISA Diagnostic Kit;**  **Correction**

**AGENCY :**  Science and Technology Directorate, Plum Island Animal Disease Center, Department of Homeland Security.

**ACTION :**  Notice of intent; correction.

**SUMMARY :**  The Department of Homeland Security Science and Technology Directorate (DHS S&T), through its Plum Island Animal Disease Center (PIADC), published a document in the Federal Register of May 16, 2013, seeking industry collaborators to aid DHS S&T in developing and validating an ELISA diagnostic kit for detection of Foot andMouth Disease Virus (FMDV) nonstructural proteins. The document did not specify dates for when the submission of proposals are due.

**FOR FURTHER INFORMATION CONTACT :**  Angela Ervin, 202–254–5624.

Correction

In the Federal Register of May 16, 2013, in FR Doc. DHS–2013–0036, on page 1, in the third column, correct the

**DATES** caption to read:

**DATES :**  Submit proposals on or before August 8, 2013.

Correction

In the Federal Register of May 16, 2013, in FR Doc. DHS–2013–0036, on


### 42533 Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices

page 1, in the third column, correct the

**ADDRESSES** caption to read:

**ADDRESSES :**  Mail comments and requests to participate to Dr. Angela Ervin, (ATTN: Angela Ervin, 245 Murray Lane SW., Washington, DC 20528–0075). Submit electronic proposals, along with comments and other data to Angela.Ervin@hg.dhs.gov on or before August 8, 2013.

Dated: July 8, 2013. James Johnson, Director, Office of National Laboratories.
[FR Doc. 2013–16952 Filed 7–15–13; 8:45 am]

**BILLING CODE 9910–9F–P**

**DEPARTMENT OF HOMELAND SECURITY** 

**Coast Guard**

**[USCG–2013–0133]**

**Collection of Information Under Review by Office of Management and**  **Budget**

**AGENCY :**  Coast Guard, DHS.

**ACTION :**  Thirty-day notice requesting
comments.

**SUMMARY :**  In compliance with the Paperwork Reduction Act of 1995 the U.S. Coast Guard is forwarding an Information Collection Request (ICR), abstracted below, to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an revision of a currently approved collection of information: 1625–0056; Labeling Required In 33 CFR parts 181 and 183 and 46 CFR 25.10–3. Our ICR describes the information we seek to collect from the public. Review and comments by OIRA ensure we only impose paperwork burdens commensurate with our performance of duties.

**DATES :**  Comments must reach the Coast Guard and OIRA on or before August 15,
2013.

**ADDRESSES :**  You may submit comments identified by Coast Guard docket number [USCG–2013–0133] to the Docket Management Facility (DMF) at the U.S. Department of Transportation (DOT) and/or to OIRA. To avoid duplicate submissions, please use only one of the following means:

(1) Online: (a) To Coast Guard docket
at http://www.regulations.gov. (b) To OIRA by email via: OIRAsubmission@omb.eop.gov.

(2) Mail: (a) DMF (M–30), DOT, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue SE., Washington, DC 20590–0001. (b) To OIRA, 725 17th Street NW., Washington, DC 20503, attention Desk Officer for the Coast Guard.

(3) Hand Delivery: To DMF address above, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The telephone number is 202–
366–9329.

(4) Fax: (a) To DMF, 202–493–2251. (b) To OIRA at 202–395–6566. To ensure your comments are received in a timely manner, mark the fax, attention Desk Officer for the Coast Guard.

The DMF maintains the public docket for this Notice. Comments and material received from the public, as well as documents mentioned in this Notice as being available in the docket, will become part of the docket and will be available for inspection or copying at room W12–140 on the West Building Ground Floor, 1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find the docket on the Internet at http://www.regulations.gov.

A copy of the ICR is available through the docket on the Internet at http:// www.regulations.gov. Additionally, copies are available from: Commandant (CG–611), ATTN: Paperwork Reduction Act Manager, U.S. Coast Guard, 2100 2nd St. SW., STOP 7101, Washington, DC 20593–7101.

**FOR FURTHER INFORMATION CONTACT :**  Contact Mr. Anthony Smith, Office of Information Management, telephone 202–475–3532 or fax 202–475–3929, for questions on these documents. Contact Ms. Barbara Hairston, Program Manager, Docket Operations, 202–366–9826, for questions on the docket.

**SUPPLEMENTARY INFORMATION :**  Public Participation and Request for Comments

This Notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection’s purpose, the Collection’s likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection.

The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the Collection; (2) the accuracy of the estimated burden of the Collection; (3) ways to enhance the quality, utility, and clarity of information subject to the Collection; and (4) ways to minimize the burden of the Collection on respondents, including the use of automated collection techniques or other forms of information technology. These comments will help OIRA determine whether to approve the ICR referred to in this Notice.

We encourage you to respond to this request by submitting comments and related materials. Comments to Coast Guard or OIRA must contain the OMB Control Number of the ICR. They must also contain the docket number of this request, [USCG 2013–0133], and must be received by August 15, 2013. We will post all comments received, without change, to http://www.regulations.gov. They will include any personal information you provide. We have an agreement with DOT to use their DMF. Please see the ‘‘Privacy Act’’ paragraph below. Submitting Comments

If you submit a comment, please include the docket number [USCG– 2013–0133], indicate the specific section of the document to which each comment applies, providing a reason for each comment. You may submit your comments and material online (via http://www.regulations.gov ), by fax, mail, or hand delivery, but please use only one of these means. If you submit a comment online via www.regulations.gov, it will be considered received by the Coast Guard when you successfully transmit the comment. If you fax, hand deliver, or mail your comment, it will be considered as having been received by the Coast Guard when it is received at the DMF. We recommend you include your name, mailing address, an email address, or other contact information in the body of your document so that we can contact you if we have questions regarding your submission.

You may submit comments and material by electronic means, mail, fax, or delivery to the DMF at the address under **ADDRESSES** , but please submit them by only one means. To submit your comment online, go to http:// www.regulations.gov, and type ‘‘USCG– 2013–0133’’ in the ‘‘Keyword’’ box. If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8 1 ⁄ 2 by 11 inches, suitable for copying and electronic filing. If you submit comments by mail and would like to know that they reached the Facility, please enclose a stamped, self-addressed